PE Goss
Universidade Federal de Minas Gerais · 46 works · 371 citations · h-index 10
Top works
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- Mutation analysis of the BRCA2 gene in 49 site–specific breast cancer families
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
- Estrogen and the Risk of Breast Cancer
- Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer
- A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
- Breast cancer in China
- Physical and Psychological Morbidity After Axillary Lymph Node Dissection for Breast Cancer
- Planning cancer control in Latin America and the Caribbean
- Challenges to effective cancer control in China, India, and Russia
- Exemestane for Breast-Cancer Prevention in Postmenopausal Women
- Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
- Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER
- Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer
- Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
- Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population